Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab + Chemotherapy +/- Fianlimab in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
NCT07346196Phase 2Not yet recruiting
- Sponsor
- University of Chicago
- Start
- Feb 2027
- Primary completion
- Aug 2031
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of fianlimab in squamous cell carcinoma of the head and neck (HNSCC), sponsored by University of Chicago. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
fianlimab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT07346196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07346196.